Drugs / VB10.2210
last change May 2023 re-read 3 minutes ago

VB10.2210

Developed for
COVID-19
Investigated by
Nykode Therapeutics ASA · Vaccibody AS

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05069623 Nov 2021 → Dec 2022 COVID-19 Nykode Therapeutics ASA Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as VB10.2210 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05069623 ↗